| pubmed-article:10626755 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10626755 | lifeskim:mentions | umls-concept:C0028978 | lld:lifeskim |
| pubmed-article:10626755 | lifeskim:mentions | umls-concept:C1332828 | lld:lifeskim |
| pubmed-article:10626755 | lifeskim:mentions | umls-concept:C0183683 | lld:lifeskim |
| pubmed-article:10626755 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:10626755 | lifeskim:mentions | umls-concept:C0052430 | lld:lifeskim |
| pubmed-article:10626755 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:10626755 | pubmed:dateCreated | 2000-1-28 | lld:pubmed |
| pubmed-article:10626755 | pubmed:abstractText | The purpose of the study was to determine the enantiomer pharmacokinetics of omeprazole and 5-hydroxy-omeprazole before and after administration of the antimalarial artemisinin to confirm artemisinin's ability to induce CYP2C19. Nine healthy male Vietnamese subjects were given a single 20 mg dose of omeprazole orally 1 week before (day - 7) artemisinin administration. Artemisinin was then given orally (500 mg) for 7 days (days 1-7). On days 1 and 7, a single 20 mg dose of omeprazole was coadministered with artemisinin. After a washout period of 6 days, a single 20 mg dose of omeprazole was again administered together with a single 500 mg of artemisinin (day 14). Stereoselective pharmacokinetics of omeprazole and 5-hydroxyomeprazole was determined on days of omeprazole administration. Seven days of artemisinin administration significantly decreased the AUC of both omeprazole enantiomers (day 7), compared with day 1 (P < 0.001). All values were normalized after the washout period. Artemisinin increased the AUC ratio of R-5-hydroxyomeprazole/R-omeprazole significantly (P < 0.01) on day 7. The AUC ratio of omeprazole sulphone/S-omeprazole did not differ between study days. Artemisinin decreased the AUC of S-omeprazole to the same extent as that of R-omeprazole in extensive CYP2C19 metabolizers. suggesting that artemisinin induces a different enzyme in addition to CYP2C19. These results support and strengthen earlier findings that artemisinin induces CYP2C19 as well as at least one enzyme other than CYP3A4. | lld:pubmed |
| pubmed-article:10626755 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10626755 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10626755 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10626755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10626755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10626755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10626755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10626755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10626755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10626755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10626755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10626755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10626755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10626755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10626755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10626755 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10626755 | pubmed:issn | 0767-3981 | lld:pubmed |
| pubmed-article:10626755 | pubmed:author | pubmed-author:BertilssonLL | lld:pubmed |
| pubmed-article:10626755 | pubmed:author | pubmed-author:MiharaKK | lld:pubmed |
| pubmed-article:10626755 | pubmed:author | pubmed-author:AshtonMM | lld:pubmed |
| pubmed-article:10626755 | pubmed:author | pubmed-author:TybringGG | lld:pubmed |
| pubmed-article:10626755 | pubmed:author | pubmed-author:RAYJ NJN | lld:pubmed |
| pubmed-article:10626755 | pubmed:author | pubmed-author:SvenssonU SUS | lld:pubmed |
| pubmed-article:10626755 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10626755 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:10626755 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10626755 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10626755 | pubmed:pagination | 671-5 | lld:pubmed |
| pubmed-article:10626755 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10626755 | pubmed:meshHeading | pubmed-meshheading:10626755... | lld:pubmed |
| pubmed-article:10626755 | pubmed:meshHeading | pubmed-meshheading:10626755... | lld:pubmed |
| pubmed-article:10626755 | pubmed:meshHeading | pubmed-meshheading:10626755... | lld:pubmed |
| pubmed-article:10626755 | pubmed:meshHeading | pubmed-meshheading:10626755... | lld:pubmed |
| pubmed-article:10626755 | pubmed:meshHeading | pubmed-meshheading:10626755... | lld:pubmed |
| pubmed-article:10626755 | pubmed:meshHeading | pubmed-meshheading:10626755... | lld:pubmed |
| pubmed-article:10626755 | pubmed:meshHeading | pubmed-meshheading:10626755... | lld:pubmed |
| pubmed-article:10626755 | pubmed:meshHeading | pubmed-meshheading:10626755... | lld:pubmed |
| pubmed-article:10626755 | pubmed:meshHeading | pubmed-meshheading:10626755... | lld:pubmed |
| pubmed-article:10626755 | pubmed:meshHeading | pubmed-meshheading:10626755... | lld:pubmed |
| pubmed-article:10626755 | pubmed:meshHeading | pubmed-meshheading:10626755... | lld:pubmed |
| pubmed-article:10626755 | pubmed:meshHeading | pubmed-meshheading:10626755... | lld:pubmed |
| pubmed-article:10626755 | pubmed:meshHeading | pubmed-meshheading:10626755... | lld:pubmed |
| pubmed-article:10626755 | pubmed:meshHeading | pubmed-meshheading:10626755... | lld:pubmed |
| pubmed-article:10626755 | pubmed:meshHeading | pubmed-meshheading:10626755... | lld:pubmed |
| pubmed-article:10626755 | pubmed:meshHeading | pubmed-meshheading:10626755... | lld:pubmed |
| pubmed-article:10626755 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10626755 | pubmed:articleTitle | Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19. | lld:pubmed |
| pubmed-article:10626755 | pubmed:affiliation | Department of Medical Laboratory Sciences and Technology, Karolinska Institute, Huddinge University Hospital, Sweden. | lld:pubmed |
| pubmed-article:10626755 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10626755 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
